FDA approval summary: Sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors

Oncologist

Volumn 17, Issue 8, 2012, Pages 1108-1113

  Blumenthal, Gideon M ^a   Cortazar, Patricia ^a   Zhang, Jenny J ^a   Tang, Shenghui ^a   Sridhara, Rajeshwari ^a   Murgo, Anthony ^a   Justice, Robert ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Pancreatic neuroendocrine tumor; Sunitinib

Indexed keywords

PLACEBO; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CONTROLLED STUDY; DEATH; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HAIR COLOR; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DRUG APPROVAL; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865228142     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0044     Document Type: Article

References (12)

1. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
2. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:108-118.
3. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-1194.
4. Kouvaraki MA, Ajani JA, Wolff R et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
5. Bergers G, Song S, Meyer-MorseNet al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295.
6. Pietras K, Hanahan D. Amultitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952.
7. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.
8. Dodd LE, Korn EL, Freidlin B et al. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? J Clin Oncol 2008;26:3791-3796.
9. Ellenberg SS, DeMets DL, Fleming TR. Bias and trials stopped early for benefit. JAMA 2010;304:158.
10. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
11. Korn EL, Freidlin B, Abrams JS. Overall Survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-2342.
12. Jiao Y, Edil BH, de Wilde RF et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331: 1199-1203.